The reduced vascular integrity that occurs in the absence of PD-1 signaling provides a significant hurdle for PD-1 immunotherapy because inhibiting PD-1 may increase the risk of heart attacks, strokes, and edema by altering the permeability of the vascular barrier (138). This evidence concerns the gene PDCD1 and myocardial infarction.